NCT02078999

Brief Summary

To evaluate in a cohort of patients on mechanical ventilation, for non-infectious reasons and for documented sepsis of pulmonary as well as non-pulmonary origin, the bacterial load, procalcitonine (PCT), C-Reactive Protein (CRP), temperature, White cell count (WCC), American College of Chest Physicians/Society of Critical Care Medicine (ACCP/SCCM) consensus conference criteria, Sequential Organ Failure Assessment score (SOFA) and simplified Clinical Pulmonary Infection Score (CPIS) through the mechanical ventilation period

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
211

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Sep 2008

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

September 1, 2008

Completed
2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 1, 2010

Completed
1.9 years until next milestone

First Submitted

Initial submission to the registry

August 3, 2012

Completed
1.6 years until next milestone

First Posted

Study publicly available on registry

March 5, 2014

Completed
1.5 years until next milestone

Study Completion

Last participant's last visit for all outcomes

September 1, 2015

Completed
Last Updated

April 4, 2017

Status Verified

April 1, 2017

Enrollment Period

2 years

First QC Date

August 3, 2012

Last Update Submit

April 3, 2017

Conditions

Keywords

Mechanical ventilation, procalcitonin, c-reactive protein

Outcome Measures

Primary Outcomes (1)

  • Procalcitonine (PCT) levels evolution

    Procalcitonin (PCT) levels assessed daily up to 21 days

    Up to 21 days

Secondary Outcomes (2)

  • C-Reactive Protein (CRP)

    Up to 21 days

  • Biomarkers at day of Ventilator-Adquired Pneumonia (VAP)

    Up to 21 days

Study Arms (3)

Control Grup

* Daily clinical data collection * Quantitative tracheal aspirates (QTA) every 3 days * Deep freeze serum samples for posterior analysis every day (two aliquots). * In patients with documented pneumonia daily collection of the following variables will continue: CRP, PCT, ABG, mechanical ventilation parameters, ACCP/SCCM consensus conference criteria, simplified CPIS, SOFA.

Patients with pulmonary infection

* Daily clinical data collection * Quantitative tracheal aspirates (QTA) every 3 days * Deep freeze serum samples for posterior analysis every day (two aliquots). * In patients with documented pneumonia daily collection of the following variables will continue: CRP, PCT, ABG, mechanical ventilation parameters, ACCP/SCCM consensus conference criteria, simplified CPIS, SOFA.

Patients with extrapulmonary infection

* Daily clinical data collection * Quantitative tracheal aspirates (QTA) every 3 days * Deep freeze serum samples for posterior analysis every day (two aliquots). * In patients with documented pneumonia daily collection of the following variables will continue: CRP, PCT, ABG, mechanical ventilation parameters, ACCP/SCCM consensus conference criteria, simplified CPIS, SOFA.

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

Patients admitted in the ICU

You may qualify if:

  • Patients admitted in the ICU, with an expected length of mechanical ventilation \> 3 days.
  • Not receiving antibiotics for \>24 hrs before ICU admission- An expected length of mechanical ventilation \> 3 days

You may not qualify if:

  • Patients \<18 yrs old
  • Pregnancy and lactation
  • Fulminant hepatic failure
  • Pancreatitis
  • Patients with the diagnosis of disseminated cancer, expected to die or undergo withdrawal of treatment within 72 hours after enrolment.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Hospital Parc TaulĂ­

Sabadell, Barcelona, 08208, Spain

Location

Related Publications (4)

  • Povoa P, Martin-Loeches I, Ramirez P, Bos LD, Esperatti M, Silvestre J, Gili G, Goma G, Berlanga E, Espasa M, Goncalves E, Torres A, Artigas A. Biomarker kinetics in the prediction of VAP diagnosis: results from the BioVAP study. Ann Intensive Care. 2016 Dec;6(1):32. doi: 10.1186/s13613-016-0134-8. Epub 2016 Apr 14.

  • Martin-Loeches I, Bos LD, Povoa P, Ramirez P, Schultz MJ, Torres A, Artigas A. Tumor necrosis factor receptor 1 (TNFRI) for ventilator-associated pneumonia diagnosis by cytokine multiplex analysis. Intensive Care Med Exp. 2015 Dec;3(1):26. doi: 10.1186/s40635-015-0062-1. Epub 2015 Sep 16.

  • Ceccato A, Camprubi-Rimblas M, Bos LDJ, Povoa P, Martin-Loeches I, Forne C, Areny-Balaguero A, Campana-Duel E, Morales-Quinteros L, Quero S, Ramirez P, Esperatti M, Torres A, Blanch L, Artigas A. Evaluation of the Kinetics of Pancreatic Stone Protein as a Predictor of Ventilator-Associated Pneumonia. Biomedicines. 2023 Sep 29;11(10):2676. doi: 10.3390/biomedicines11102676.

  • Povoa P, Martin-Loeches I, Ramirez P, Bos LD, Esperatti M, Silvestre J, Gili G, Goma G, Berlanga E, Espasa M, Goncalves E, Torres A, Artigas A. Biomarkers kinetics in the assessment of ventilator-associated pneumonia response to antibiotics - results from the BioVAP study. J Crit Care. 2017 Oct;41:91-97. doi: 10.1016/j.jcrc.2017.05.007. Epub 2017 May 8.

Biospecimen

Retention: SAMPLES WITHOUT DNA

Bronchoalveolar lavage,biochemical lab,exhaled air.

MeSH Terms

Conditions

Pneumonia, Ventilator-Associated

Condition Hierarchy (Ancestors)

Healthcare-Associated PneumoniaCross InfectionInfectionsPneumoniaRespiratory Tract InfectionsLung DiseasesRespiratory Tract DiseasesIatrogenic DiseaseDisease AttributesPathologic ProcessesPathological Conditions, Signs and Symptoms

Study Officials

  • torres antonio, doctor

    hospital vall hebron barcelona

    PRINCIPAL INVESTIGATOR
  • palomar mercedes, doctor

    Hospital Clinic i provincial de Barcelona

    PRINCIPAL INVESTIGATOR
  • povoa pedro, doctor

    Centro hospitalario de lisboa occidental

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
OTHER
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
PhD

Study Record Dates

First Submitted

August 3, 2012

First Posted

March 5, 2014

Study Start

September 1, 2008

Primary Completion

September 1, 2010

Study Completion

September 1, 2015

Last Updated

April 4, 2017

Record last verified: 2017-04

Locations